Akeso and Summit Therapeutics' PD-1xVEGF drug has delivered its first overall survival win in a phase 3 trial. Fosun Pharma out-licensed another immune disease candidate. | Akeso and Summit ...

The drug rilzabrutinib, which is now approved as Wayrilz in immune thrombocytopenia (ITP), has been hailed (PDF) by Sanofi as a potential “multi-indication blockbuster” that could deliver 2 billion to ...

Aiming to deliver blockbuster sales of its Alzheimer’s disease-fighting antibody Leqembi in its 2027 fiscal year, Eisai has cleared a key regulatory hurdle in its quest to grow the medicine's reach | ...

Novo Nordisk’s blockbuster obesity drug Wegovy is set to be greeted by physician enthusiasm and "swift" adoption as it taps into a new liver disease market in the U.S. | Wegovy's mechanism of action ...

Flying high after an FDA approval four months ago to treat generalized myasthenia gravis (gMG), Johnson & Johnson’s much-touted Imaavy (nipocalimab) has taken a hit, coming up short as part of a ...

Pfizer is taking a curtain call for Vyndaqel, the low-dose version of its blockbuster tafamidis franchise for the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM). | Pfizer is taking ...

Amid a growing push for more direct-to-consumer access to some of the world’s most popular drugs, Eli Lilly has inked a deal with China’s JD Health to sell its obesity, Type 2 diabetes and alopecia ...

As AstraZeneca charts a lucrative new path for FluMist with a self-administration nod and an at-home delivery service for the nasal spray-based influenza vaccine, the school that had a hand in the | ...

Ahead of plans to raise the price of its Type 2 diabetes and obesity blockbuster in the U.K. next month, Eli Lilly is temporarily halting Mounjaro orders from the country. | Ahead of plans to raise ...

Amid uncertainty over how the Trump administration would approach mRNA COVID-19 vaccines for the upcoming respiratory virus ...

A newly published report developed by a group of partners, including Sanofi, shines a light on the far-reaching impacts of ...

China biotech RemeGen and its new U.S. partner Vor Bio are on a roll with their first-in-class autoimmune treatment ...